Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own0.50% Shs Outstand147.12M Perf Week-1.96%
Market Cap9.84B Forward P/E- EPS next Y-1.20 Insider Trans12.72% Shs Float146.79M Perf Month-0.52%
Income-186.60M PEG- EPS next Q-0.20 Inst Own99.80% Short Float3.91% Perf Quarter10.51%
Sales627.10M P/S15.69 EPS this Y-34.70% Inst Trans-2.03% Short Ratio5.37 Perf Half Y-17.61%
Book/sh10.01 P/B6.68 EPS next Y7.70% ROA-8.70% Target Price83.13 Perf Year-8.87%
Cash/sh5.69 P/C11.76 EPS next 5Y25.00% ROE-13.50% 52W Range55.04 - 84.25 Perf YTD-4.92%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-18.68% Beta0.99
Dividend %- Quick Ratio6.20 Sales past 5Y13.10% Gross Margin83.00% 52W Low24.47% ATR1.84
Employees1341 Current Ratio7.30 Sales Q/Q40.20% Oper. Margin-23.00% RSI (14)53.97 Volatility2.11% 2.72%
OptionableYes Debt/Eq0.45 EPS Q/Q-53.30% Profit Margin-29.80% Rel Volume0.57 Prev Close66.89
ShortableYes LT Debt/Eq0.45 EarningsOct 22 AMC Payout- Avg Volume1.07M Price68.51
Recom2.00 SMA20-1.23% SMA505.61% SMA2002.83% Volume532,859 Change2.42%
19-Feb-14Reiterated Barclays Equal Weight $73 → $76
14-Jan-14Reiterated Deutsche Bank Buy $75 → $85
10-Jan-14Downgrade Barclays Overweight → Equal Weight $75 → $73
25-Oct-13Reiterated Barclays Overweight $70 → $75
18-Sep-13Downgrade Stifel Buy → Hold
26-Jul-13Reiterated Stifel Buy $67 → $70
03-Apr-13Reiterated Barclays Overweight $54 → $70
20-Mar-13Reiterated RBC Capital Mkts Outperform $58 → $64
20-Mar-13Reiterated Deutsche Bank Hold $45 → $59
22-Feb-13Reiterated RBC Capital Mkts Outperform $55 → $58
01-Feb-13Reiterated UBS Buy $53 → $67
22-Jan-13Upgrade Stifel Nicolaus Hold → Buy $67
06-Nov-12Reiterated Barclays Overweight $46 → $54
06-Nov-12Downgrade Brean Capital Buy → Hold
28-Sep-12Reiterated Summer Street Research Buy $45 → $52
27-Aug-12Downgrade Deutsche Bank Buy → Hold $40 → $45
24-Aug-12Initiated Barclays Overweight $46
12-Apr-12Initiated UBS Buy $43
26-Mar-12Initiated Canaccord Genuity Buy $43
19-Mar-12Upgrade Brean Murray Hold → Buy $41
15-Sep-14 08:00AM  BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines GlobeNewswire
10-Sep-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences in London GlobeNewswire
05-Sep-14 04:35PM  Merck KGaA's Kuvan Effective in Under-4 Year Olds Zacks
03-Sep-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
31-Aug-14 03:00AM  Early data suggest Sanofi, Regeneron drug may halve heart risk Reuters
28-Aug-14 01:04PM  NVO, BMRN And ILMN, 3 Health Care Stocks Pushing The Sector Lower at TheStreet
27-Aug-14 04:20PM  BioMarin Cuts '14 Revenue View after Voucher Sale Evaluation Zacks
06:40AM  Can BioMarin Pharmaceutical (BMRN) Run Higher on Strong Earnings Estimate Revisions? Zacks
26-Aug-14 04:21PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Results of Operations and Financial Condition EDGAR Online
19-Aug-14 08:00AM  BioMarin to Present at Upcoming Investor Conferences GlobeNewswire
14-Aug-14 01:32PM  Temasek Adds China Holdings With JD.com, Cheetah Stakes at Bloomberg
08-Aug-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
10:29AM  Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The Wall Street Transcript Wall Street Transcript
07-Aug-14 11:40AM  NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Zacks
07:04AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
06-Aug-14 04:02PM  BioMarin Weathers The Storm Benzinga
05-Aug-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
07:33AM  Saving kids: When unapproved drugs are the only hope at CNBC
01-Aug-14 01:28PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
31-Jul-14 04:00PM  BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Zacks
01:34PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
30-Jul-14 04:08PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Sells Priority Review Voucher for $67.5 Million GlobeNewswire
04:01PM  BioMarin Announces Second Quarter 2014 Financial Results GlobeNewswire
11:04AM  Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Zacks
07:07AM  Q2 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN
23-Jul-14 02:15PM  [video] What's coming in biotech? at CNBC
12:20PM  Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines Zacks
12:10PM  Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Zacks
08:00AM  Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation GlobeNewswire
18-Jul-14 08:21AM  Zacks Rank #1 Additions for Friday Zacks +5.88%
16-Jul-14 03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
15-Jul-14 06:04AM  Cramer's Lightning Round - BioMarin Deserves To Be Higher (7/14/14) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Wait on Whole Foods at TheStreet
14-Jul-14 06:52PM  Lightning Round: Whole Foods, Apache & more at CNBC
03:45PM  Will Johnson & Johnson (JNJ) Beat this Earnings Season? Zacks
09-Jul-14 08:00AM  BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET GlobeNewswire
08-Jul-14 05:10PM  BioMarin's Vimizim Gets Canadian Nod Zacks
07-Jul-14 08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome PR Newswire
08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome CNW Group
03-Jul-14 07:06AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
30-Jun-14 05:00PM  Biogen Hemophilia Drugs Launch Into The Unknown at Investor's Business Daily
02:06AM  Lifting the Curtain on Healthcare's Most Expensive Drugs at Motley Fool
20-Jun-14 02:19PM  Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate at TheStreet +5.90%
02:19PM  Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate
12-Jun-14 02:11PM  Amicus Therapeutics Still A "Show Me" Story at Seeking Alpha
02:11PM  Amicus Therapeutics Still A "Show Me" Story
08:30AM  Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More at 24/7 Wall St.
07:53AM  How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? at TheStreet
07:53AM  How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today?
10-Jun-14 11:02AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a EDGAR Online
11:02AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
08:00AM  BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th GlobeNewswire
08:00AM  BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
09-Jun-14 07:54AM  How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? at TheStreet
07:54AM  How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today?
03-Jun-14 01:02PM  Drugs Stocks On The Rise With Help From 3 Stocks at TheStreet +6.17%
01:02PM  Drugs Stocks On The Rise With Help From 3 Stocks
12:01PM  Life After Pfizer: AstraZeneca Hopes for Oncology Success at Motley Fool
12:01PM  Life After Pfizer: AstraZeneca Hopes for Oncology Success
29-May-14 10:40AM  BioMarin's Pipeline Advances Zacks
10:40AM  BioMarin's Pipeline Advances
28-May-14 08:32AM  Retrophin Names Aselage COO at theflyonthewall.com
08:32AM  Retrophin Names Aselage COO
27-May-14 08:40AM  BioMarin doses first patient in Phase 3 INSPIRE trial with BMN 701 at theflyonthewall.com
08:00AM  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease GlobeNewswire
23-May-14 08:31AM  BioMarin has a conference call hosted by JPMorgan at theflyonthewall.com
15-May-14 09:47AM  Temasek Boosted Stake in U.S. Health Care Industry Last Quarter at Bloomberg
06:47AM  BioMarin data compares well as monotherapy, says William Blair at theflyonthewall.com
05:40AM  ASCO abstracts 'surprisingly bland,' says Piper Jaffray at theflyonthewall.com
14-May-14 10:30AM  Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders at TheStreet
09-May-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
08-May-14 06:00AM  'Mad Money' Lightning Round: BioMarin Is for Real at TheStreet
04:29AM  Cramer's Lightning Round - BioMarin Is A Biotech Survivor (5/7/14) at Seeking Alpha
06-May-14 06:48PM  Lightning Round: Westport Innovations, Opko & More at CNBC
08:00AM  BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th GlobeNewswire
02-May-14 03:00PM  Loss at BioMarin Narrower Than Expected Zacks
12:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09:13AM  BioMarin says change ups chance to hit cognition endpoint, says Janney Capital at theflyonthewall.com
06:11AM  BioMarin says BMN 165-302 study to be available in Q4 of 2015 theflyonthewall.com
12:50AM  BioMarin Pharmaceutical's CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
01-May-14 06:14PM  BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales at Motley Fool
04:49PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:05PM  BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress GlobeNewswire
09:32AM  Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics Inc. at Motley Fool
07:07AM  Q1 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN
29-Apr-14 06:32PM  Better Biotech Buy: Vertex Pharmaceuticals Incorporated vs. BioMarin Pharmaceutical Inc. at Motley Fool
28-Apr-14 06:36PM  Cramer: Momentum stocks to fall much further? at CNBC
03:18PM  Cancer and Hepatitis C Treatment Breakthroughs Boost Pharma Stocks: Citigroup Investment Global Head of Healthcare Research & Analysis Andrew Baum, M.D. Interviews with the Wall Street Transcript Wall Street Transcript
01:08PM  Obamacare Worries Subside as Orphan Drugs and Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sec Wall Street Transcript
11:06AM  BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages GlobeNewswire
23-Apr-14 08:48AM  Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases at Seeking Alpha
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
16-Apr-14 09:07AM  Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data Zacks +5.43%
08:00AM  BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET GlobeNewswire
14-Apr-14 06:15PM  [video] The IPO plague at CNBC
08:22AM  BioMarin says FDA extends Kuvan market exclusivity by six months theflyonthewall.com
08:00AM  FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets GlobeNewswire
11-Apr-14 06:25AM  Cramer's Lightning Round - The IPOs Are A Curse On The Market (4/10/14) at Seeking Alpha -6.59%
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise12.995,00064,95055,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale70.005,000350,00050,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise12.9910,000129,90060,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale67.4110,000674,09650,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Option Exercise12.995,00064,95055,740Jan 06 04:08 PM
FUCHS HENRY JEVP, Chief Medical OfficerJan 02Sale68.9791663,17242,350Jan 06 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Sale68.905,000344,48350,740Jan 06 04:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale68.7110,000687,14350,740Dec 27 12:07 PM
GREY MICHAEL GDirectorDec 11Option Exercise21.7130,000651,30053,050Dec 13 06:07 PM
GREY MICHAEL GDirectorDec 11Sale69.6630,0002,089,68023,050Dec 13 06:07 PM
LEWIS ALANDirectorDec 09Option Exercise30.5222,500686,77541,800Dec 11 08:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Option Exercise19.4413,026253,18327,906Dec 11 07:15 PM
LAWLIS V BRYANDirectorDec 09Sale69.762,900202,30111,400Dec 11 07:17 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Sale69.5513,026906,01014,880Dec 11 07:15 PM
LEWIS ALANDirectorDec 09Sale69.9122,5001,572,98219,300Dec 11 08:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 05Sale69.705,000348,48550,740Dec 09 07:42 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Option Exercise39.069,000351,54046,950Dec 04 04:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Sale70.149,000631,27337,950Dec 04 04:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 14Option Exercise12.995,00064,95050,740Nov 18 05:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Option Exercise12.995,00064,95050,740Nov 07 05:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Sale62.365,000311,77945,740Nov 07 05:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 01Sale63.16996,25314,880Nov 05 07:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Option Exercise12.9910,000129,90055,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Sale62.7210,000627,15545,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Option Exercise12.992,00025,98047,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 16Sale67.732,000135,45045,740Oct 18 05:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 10Sale66.763,000200,29145,740Oct 15 08:17 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Option Exercise11.0510,000110,50053,266Sep 23 04:37 PM
FUCHS HENRY JEVP, Chief Medical OfficerSep 19Sale80.1910,000801,90043,266Sep 23 04:37 PM